Technology Prognosis

tracking technologies before you have to make a decision

Azedra (Iobenguane I 131)

August 9, 2018

Azedra (iobenguane I 131) is a radiotherapeutic product for treatment of adult and pediatric patients 12 years of age and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (PPGL) who require systemic anticancer therapy. Azedra is the first drug approved to treat patients with PPGL who require systemic treatment.